GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8F) » Definitions » Debt-to-EBITDA

Biofrontera AG (XTER:B8F) Debt-to-EBITDA : 0.12 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Biofrontera AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.47 Mil. Biofrontera AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.68 Mil. Biofrontera AG's annualized EBITDA for the quarter that ended in Dec. 2023 was €10.00 Mil. Biofrontera AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Biofrontera AG's Debt-to-EBITDA or its related term are showing as below:

XTER:B8F' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.57   Med: -0.85   Max: 21.4
Current: -0.16

During the past 13 years, the highest Debt-to-EBITDA Ratio of Biofrontera AG was 21.40. The lowest was -5.57. And the median was -0.85.

XTER:B8F's Debt-to-EBITDA is ranked worse than
100% of 655 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs XTER:B8F: -0.16

Biofrontera AG Debt-to-EBITDA Historical Data

The historical data trend for Biofrontera AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Debt-to-EBITDA Chart

Biofrontera AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.40 -5.57 0.08 -0.04 -0.87

Biofrontera AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.11 0.39 -0.13 0.12

Competitive Comparison of Biofrontera AG's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's Debt-to-EBITDA falls into.



Biofrontera AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Biofrontera AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.468 + 0.678) / -1.321
=-0.87

Biofrontera AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.468 + 0.678) / 10
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Biofrontera AG  (XTER:B8F) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Biofrontera AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera AG (XTER:B8F) Business Description

Traded in Other Exchanges
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8F) Headlines

No Headlines